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Abstract
Background: Radiotherapy technology is expanding rapidly. Volumetric Modulated Arc Therapy (VMAT)
technologies such as RapidArc
® (RA) may be a more efficient way of delivering intensity-modulated radiotherapy-
like (IM) treatments. This study is an audit of the RA experience in an Australian department with a planning and
economic comparison to IM.
Methods: 30 consecutive prostate cancer patients treated radically with RA were analyzed. Eight RA patients
treated definitively were then completely re-planned with 3D conformal radiotherapy (3D); and a conventional
sliding window IM technique; and a new RA plan. The acceptable plans and their treatment times were compared
and analyzed for any significant difference. Differences in staff costs of treatment were computed and analyzed.
Results: Thirty patients had been treated to date with eight being treated definitely to at least 74 Gy, nine post
high dose brachytherapy (HDR) to 50.4Gy and 13 post prostatectomy to at least 64Gy. All radiotherapy courses
were completed with no breaks. Acute rectal toxicity by the RTOG criteria was acceptable with 22 having no
toxicity, seven with grade 1 and one had grade 2.
Of the eight re-planned patients, none of the 3D (three-dimensional conformal radiotherapy) plans were
acceptable based on local guidelines for dose to organs at risk. There was no statistically significant difference in
planning times between IM and RA (p = 0.792). IM had significantly greater MUs per fraction (1813.9 vs 590.2 p <
0.001), total beam time per course (5.2 vs 3.1 hours, p = 0.001) and average treatment staff cost per patient
radiotherapy course ($AUD489.91 vs $AUD315.66, p = 0.001). The mean saving in treatment staff cost for RA
treatment was $AUD174.25 per patient.
Conclusions: 3D was incapable of covering a modern radiotherapy volume for the radical treatment of prostate
cancer. These volumes can be treated via conventional IM and RA. RA was significantly more efficient, safe and
cost effective than IM. VMAT technologies are a superior way of delivering IM-like treatments.
Keywords: Intensity-modulated radiotherapy, Volumetric modulated arc therapy, three-dimensional conformal
radiotherapy, Australia, health care cost
Background
Radiotherapy technology is expanding rapidly. Newer
technologies such as intensity modulated radiotherapy
(IM) enable better radiation dose conformality to the
target volume compared with three-dimensional
conformal radiotherapy (3D). Better dose conformality
means that the dose of radiation to the volume requir-
ing treatment can be escalated, thereby increasing can-
cer control, more volume can also be treated safely,
while simultaneously decreasing the dose to surrounding
radiation-sensitive normal tissues, thereby decreasing
radiotherapy toxicities. * Correspondence: Gerald.Fogarty@cancer.com.au
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the Australian setting compared to other developed
countries for various reasons. For example, IM has been
a standard therapy in the United States from mid-1995,
whereas in Australia it is still not offered in every
department and even then is reserved for special situa-
tions, for example, radical re-treatments and paediatric
cases. However, there have been recent developments at
a governmental level to investigate whether conventional
IM has benefits over 3-DCRT. This project will ensure
that increased government reimbursement for therapies
is based on proper evidence. This process has been fol-
lowed before with success [1].
In the meantime, IM technology has evolved even
further. IM technology can now be delivered in a more
efficient manner via Volumetric Modulated Arc Therapy
(VMAT). VMAT technologies may also be safer. Exter-
nal beam radiotherapy is delivered by a certain number
of machine monitor units (MUs), a measure of machine
radiation output. MUs are important as second cancer
risk in patients treated with radiotherapy is proportional
to how many MUs are needed per treatment course
[2,3].
The efficiency of VMAT has enabled the expansion of
IMRT-like techniques to routine treatments and not
rationed to only rare situations. The Mater Hospital in
Sydney was the first centre in the state of New South
Wales of Australia to treat with VMAT. This was possi-
ble following the installation of a new Varian
® 21iX lin-
ear accelerator, which delivers VMAT under the trade
name of RapidArc
® (RA). The department went directly
from treating with 3D to RA. Over 350 patients have
now been treated with this new technology in this cen-
tre. This study is an audit of the RA experience to
ensure that the newer therapy is recommended with
proper evidence.
Methods
The audit is of the first thirty consecutive prostate can-
cer patients that have been radically treated for prostate
cancer by one radiation oncologist with RA.
Data gathered for these prostate cancer patients
included the indication for radiation therapy. This was
either definitive radiation (74 to 78 Gy); or post surgery
radiation (64 to 66 Gy); or post high dose rate bra-
chytherapy (50.4 Gy). Also collected were total beam
time, total MUs per course and acute rectal toxicities as
per the RTOG criteria [4] up to six weeks post
radiotherapy.
Plans were accepted by the treating radiation oncolo-
gist if the IM dose constraints for external beam radio-
therapy for prostate cancer were met as per the current
local guidelines as detailed in Table 1. These constraints
are essentially from Emani et al [5].
Comparison with replanning
The RA patients treated with definitive external beam
radiotherapy were then completely re-planned with 3D;
and a conventional sliding window IM technique; and a
new RA plan. The IM technique was with a seven field
plan, RA was planned using two arcs. Planning was
done by a dosimetrist, qualified and experienced in this
type of planning, but not familiar with these particular
cases. The planning system used was Eclipse
® version
8.6 and was imported into the treatment system using
Mosaiq
® version 2.00W9. The time taken for the dosi-
metrist to plan for each of the techniques for each case
was recorded. Quality assurance on a phantom was then
performed by a qualified physicist as per local protocol
using our in-house phantom. It was assumed that there
was no need for a quality assurance of 3D.
The phantom was then treated. The default dose rate
used was 600MUs per minute. MUs per fraction were
recorded. The beam time from start to finish of each
fraction for all acceptable techniques was recorded. The
total beam time for each technique was computed by
multiplying this time by the number of fractions. The
number of fractions prescribed was the same for the
patient independent of technique. These data were then
compared and analyzed for any significant difference.
Comparison of treatment cost between IM and RA
Economic remuneration data for treatment radiation
therapists was gleaned from the current New South
Wales (NSW) award [6] (Table 2). This information on
payment per hour allowed an item for treatment staff
costs to be estimated. Labour costs were computed for
the total course. It was assumed that the treating radia-
tion therapists were on the lowest paid level qualified to
perform the relevant duties. In our NSW system, this
meant that the two therapists involved in the treatment,
Table 1 Rectal dose constraints for 3D and IM as per
local guidelines [5]
Dose (Gy) % of total Rectum receiving dose
40Gy ≤ 60% (≤35% with IM)
65Gy ≤ 40% (≤17% with IM)
70Gy ≤ 30%
75Gy ≤ 10%
Table 2 Costs of radiotherapy staff in the planning and
treatment of cancer patients as per the New South Wales
award of 2011 [6]
Position $AUD/hr
Treating Radiation therapist - level 4, grade 1, year 1 $53.43
Treating Radiation therapist - level 2, year 1 $29.37
Total labour cost of treating team $82.80
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tively. The difference in cost between the techniques
was computed by multiplying the total treatment beam
times by the staff remuneration per hour. In arriving at
the different costs, it was assumed that the only differ-
ence between the treatments was the total duration of
beam-on time from start to finish of each fraction. It
was assumed that patient setup time and position verifi-
cation, usually with an IGRT (image guided radiother-
apy) technique, was the same independent of technique.
The treatment costs of each technique were compared
and analyzed for any significant difference.
It was assumed that the following were the same inde-
pendent of the technique: time spent by the radiation
oncologist to perform contouring, plan acceptance and
to see the patients in follow up; the costs of the different
linear accelerators (as all new modern linear accelerators
are now capable of 3D, IM and VMAT); and costs of
linear accelerator commissioning by physics for the dif-
ferent techniques. The latter are not considered impor-
tant between the techniques as commissioning is a one
off cost for these machines which have a working life of
around 10 years.
Statistical analyses were conducted using the IBM
SPSS Statistic 19.0 software package. Independent and
paired t-tests were used to compare mean values where
appropriate. Two-tailed p-values < 0.05 were considered
statistically significant.
Results
Thirty consecutive prostate cancer patients treated radi-
cally via RA by one radiation oncologist in our institu-
tion were found and their characteristics are detailed in
Table 3.
Eight of these RA patients, those treated with defini-
tive external beam radiotherapy were re-planned with
3D, conventional IM and RA techniques. None of the
3D plans that were attempted were acceptable by the
local guidelines as per Table 1 for the 3D criteria. All
the RA and IM plans were acceptable according to PTV
coverage and the dose constraints for IM as detailed in
Table 1. Planning times between IM and RA (Table 4)
were not significantly different (p = 0.792). There was
significantly greater machine output (MUs) per fraction
for IM (1813.9, SD = 159.1) compared with RA (590.2,
SD = 67.1); p < 0.001.
Total treatment times (hours) were significantly
greater for IM (5.2, SD = 1.2) compared with RA (3.1,
SD = 0.5); p = 0.001 as detailed in Table 5. This table
also records the cost difference between the techniques
using the data of Table 2. The average cost per patient
for IM treatment ($ AUD 489.91, SD = $ AUD 107.53)
was significantly higher than that of RA ($AUD315.66,
SD = $ AUD 51.59), p = 0.001. The mean saving in cost
for RA treatment was $ AUD 174.25 per patient (95%
CI: $95.38-$253.11). This cost saving is only for the
wages of the treating radiation therapy staff, based on
the difference in the beam times between RA and IM.
The analyzed data of IM versus RA is summarized in
Table 6.
Discussion
In our audit, 30 prostate cancer patients treated radically
with RA by one radiation oncologist were found to be
treated with acceptable toxicity. In re-planning eight pros-
tate cancer patients treated with definitive external beam,
3D was found to be incapable of covering a more modern
radiotherapy volume even at the higher tolerances allowed
with that technique. It is therefore definitely time for Aus-
tralian radiotherapy to move on from 3D.
Modern radiotherapy volumes can be treated via
conventional IM and RA, even at the more exacting
dose constraints demanded by our local guidelines.
There was no difference in planning times between
these techniques. However, RA was significantly
superior in terms of decreased monitor units and
therefore safety as least as far as second malignancy
risk is concerned [2,3]. RA also had a decreased treat-
ment time, and so decreased treating staff time, and
therefore costs. The average total beam time per
Table 3 Indication for radiotherapy, total beam times,
monitor units and acute rectal toxicity of the first 30















Definitive 8 186 23050 4 × grade 1, 1 × grade
2
Post HDR 9 132 16496 2 × grade 1
Post
surgery
13 138 21136 1 × grade 1







RA IM RA IM
1 73 79 688 1589
2 75 82 589 1909
3 81 61 588 2025
4 85 74 506 1656
5 84 65 625 1898
6 48 72 544 1646
7 80 99 667 1889
8 87 67 515 1899
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than with RA. There was an average saving of treating
staff costs for each patient of $AUD174 with RA over
IM. RA cost only 64% of the treating staff cost of IM.
The real saving is greater, as only the treating staff
costs were computed, not the extra cost implicit in
the extra time needed for keeping the department
open with administration and nursing staff etc, nor
the extra capital costs for more buildings and
machines that would be necessary to treat the same
number of patients in a timely fashion. For interest we
looked at a group of prostate cancer patients treated
for the same indications by the same radiation oncolo-
gist and with the same machine with 3D before it was
commissioned for RA. We found that the there was
no difference in the average total beam time between
the RA and the 3D groups (p = .885). RA then com-
pares favorably with 3D from a logistical viewpoint
with similar treatment times and therefore costs. The
superior dosimetry, and monitor unit savings makes it
the preferred technique. RA overall combines the
superior dosimetry of IM, the logistics of 3D, and yet
with a better safety profile.
RA efficiency means even more. Patients are on the
hard accelerator bed for less time, so patient comfort is
improved. There is less time for internal organ intrafrac-
tion motion. Less treatment time per patient also leads
to better clinical flow. More indications for radiotherapy
can be treated with this new technique. Even palliative
regimes can now access VMAT radiotherapy e.g. whole
brain radiotherapy with simultaneous integrated boost
and hippocampal sparing [7]. Our conclusion is that RA
was superior to the other modalities, even conventional
IM.
The finding of superiority of RA in this study is
important in the Australianc o n t e x t .R Ai sj u s to n e
VMAT technology now available. Australian centres
have been plagued by skilled staff shortages and waiting
lists [8,9]. VMAT can contribute to solving these pro-
blems as well as update our treatment complexity to the
level expected of a developed country.
Conclusions
Thirty prostate cancer patients treated radically by one
radiation oncologist with Rapid Arc
® (RA), a type of
volumetric modulated arc therapy (VMAT) were treated
with acceptable toxicity. When eight of these patients
were re-planned, three dimensional conformal techni-
ques (3D) was not capable of covering the volumes
needed without exceeding local guidelines for toxicity.
RA was significantly superior to conventional intensity
modulated radiotherapy (IM) with more efficient total
treatment times, less monitor units and with no increase
in planning times. The average treatment staff cost per
patient course of radiotherapy was decreased from
$489.91 to $315.66. RA combines the superior dosimetry
of IM, the logistics of 3D, and yet with a better safety
profile.
Table 5 IM and RA treatment times and relative treatment staff costs
Pt No Dose(Gy)/fraction Total Treatment Beam Time (hours) Difference in treatment
(Time: hr/min; Cost: $)
IM RA
1 78/39 4.72 2.57 2h 9m/$178.02
2 74/37 5.80 2.97 2h 50m/$234.50
3 78/39 4.98 3.00 2h/$165.60
4 74/37 5.92 3.18 2h 43m/$224.90
5 78/39 4.05 3.57 28m/$38.64
6 74/37 4.50 2.35 2h 9m/$178.02
7 78/39 7.48 4.05 3h 27m/$285.66
8 74/37 3.93 3.13 47m/$64.86
Table 6 Comparison of IM and RA for a matched cohort of eight patients
Measure IM RA P-value
Average Plan Time (minutes) 74.9 76.6 0.792
Average MUs (SD) (Units) 1813.9 (SD = 159.1) 590.2 (SD = 67.1) <0.001
Average Treatment Time (SD)* (hours) 5.2 (SD = 1.2) 3.1 (SD = 0.5) 0.001
Average Treatment Staff Cost per Patient* $ 489.91 $ 315.66 0.001
*Total time calculated for all fractions
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